%0 Journal Article %A Robert J Young %A Paula Demétrio De Souza França %A Giacomo Pirovano %A Anna F Piotrowski %A Philip J Nicklin %A Christopher C Riedl %A Jazmin Schwartz %A Tejus A Bale %A Patrick L Donabedian %A Susanne Kossatz %A Eva M Burnazi %A Sheryl Roberts %A Serge K Lyashchenko %A Alexandra M Miller %A Nelson S. Moss %A Megan Fiasconaro %A Zhigang Zhang %A Audrey Mauguen %A Thomas Reiner %A Mark P Dunphy %T Preclinical and first-in-human-brain-cancer applications of [18F]poly-(ADP-ribose) polymerase inhibitor PET/MR %D 2020 %R 10.1101/2020.07.13.20141036 %J medRxiv %P 2020.07.13.20141036 %X We report pre-clinical and first-in-human-brain-cancer data using a targeted poly(ADP-ribose)polymerase1 (PARP1) binding PET tracer, [18F]PARPi, as a diagnostic tool to differentiate between brain cancers and treatment related changes. In a pre-clinical mouse model, we illustrated that [18F]PARPi crosses the blood-brain barrier and specifically binds to PARP1 overexpressed in cancer cell nuclei. In humans, we demonstrated high [18F]PARPi uptake on PET/MR in active brain cancers and low uptake in treatment related changes, independent of blood brain-barrier disruption. Immunohistochemistry results confirmed higher PARP1 expression in cancers than non-cancers. Specificity was also corroborated by blocking fluorescent tracer uptake with excess of unlabeled PARP inhibitor in fresh cancer tissue derived from a patient. Although larger studies are necessary to confirm and further explore this tracer, we describe an encouraging role for the use of [18F]PARPi as a diagnostic tool in evaluating patients with brain cancers and possible treatment related changes.One Sentence summary PET imaging with [18F]PARPi can differentiate active brain cancer from treatment related changes with encouraging results for use during treatment follow-up.Competing Interest StatementRJY has financial interests and received funding from Agios, and consulted for Agios, Puma, ICON, and NordicNeuroLab, unrelated to this work. NSM has consulted for AztraZeneca. TR and SK are shareholders of Summit Biomedical Imaging and co-inventors on filed U.S. patent (WO2016164771) that covers methods of use for PARPi-FL and [18F]PARPi. TR is co-inventor on U.S. patent (WO2012074840), covering the composition of matter for PARPi-FL and [18F]PARPi. TR also is a paid consultant for Theragnostics, Inc. MPD, SKL, PDSF, GP, AFP, PJN, CCR, JS, TAB, PLD, EMB, SR, AM, MF, ZZ and AM declare that they have no competing interests. This arrangement has been reviewed and approved by Memorial Sloan Kettering Cancer Center in accordance with its conflict of interest policies.Clinical TrialNCT04173104Funding StatementThis work was supported by National Institutes of Health grants P30 CA008748, R01 CA204441, R43 CA228815 the Memorial Sloan Kettering Imaging and Radiation Sciences Program and the Memorial Sloan Kettering Molecularly Targeted Intraoperative Imaging Fund. The funding sources were not involved in study design, data collection and analysis, writing of the report, or the decision to submit this article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective single center, investigator initiated pilot study (ClinicalTrials.gov NCT04173104) examined [18F]PARPi PET/MR in patients with brain cancers. The primary objective was to determine [18F]PARPi uptake in cancers and treatment related changes. The study was performed according to the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines, was compliant with the Health Insurance Portability and Accountability Act regulations and approved by the local Institutional Review Board and Privacy Board. The authors all vouch for the accuracy and completeness of the data and analyses and for the adherence of the study to the protocol. All patients provided written informed consent before enrollment.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this study are present in the paper or the Supplementary Materials. %U https://www.medrxiv.org/content/medrxiv/early/2020/07/17/2020.07.13.20141036.full.pdf